

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	11	6.9	158.3	(78.9-283.2)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	6	1.7	362.9	(132.5-789.9)	Female	2	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	20.8	86.4	(51.2-136.6)
Female	0	0.2	nc	(nc-nc)	Female	29	22.7	127.5	(85.4-183.1)
<u>Lung and Bronchus</u>									
Male	4	2.8	nc	(nc-nc)					
Female	3	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.7	74.9	(24.1-174.8)	Male	6	4.7	126.4	(46.1-275.1)
Female	2	2.1	nc	(nc-nc)	Female	0	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.3	115.2	(37.1-268.9)
Female	40	29.9	133.8	(95.6-182.2)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	10	8.2	122.7	(58.7-225.6)	<u>Ovary</u>				
Female	7	6.7	104.4	(41.8-215.2)	Female	2	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	26	25.4	102.3	(66.8-149.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	6.4	nc	(nc-nc)
Male	6	3.0	197.3	(72.0-429.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	6	6.6	91.1	(33.3-198.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	99	97.9	101.1	(82.2-123.1)
Female	1	0.8	nc	(nc-nc)	Female	88	93.0	94.6	(75.9-116.5)
<u>Lung and Bronchus</u>									
Male	17	12.2	139.6	(81.3-223.6)					
Female	9	11.3	79.8	(36.4-151.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	34.8	100.5	(70.0-139.7)	Male	32	23.5	136.3	(93.2-192.5)
Female	11	16.5	66.6	(33.2-119.2)	Female	22	23.3	94.3	(59.1-142.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	7.6	144.1	(71.8-257.8)	Male	4	7.3	nc	(nc-nc)
Female	2	7.4	nc	(nc-nc)	Female	13	7.5	173.2	(92.1-296.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	30	21.2	141.4	(95.4-201.9)
Female	169	180.0	93.9	(80.3-109.1)	Female	21	23.3	90.3	(55.9-138.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.3	79.9	(25.8-186.6)	Male	22	17.9	123.1	(77.1-186.4)
<u>Colon / Rectum</u>					Female	14	9.8	143.1	(78.2-240.1)
Male	42	39.8	105.5	(76.0-142.5)	<u>Ovary</u>				
Female	36	48.9	73.7	(51.6-102.0)	Female	9	15.8	56.9	(26.0-108.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	9.2	131.0	(67.6-228.9)	Male	10	12.8	78.2	(37.4-143.9)
Female	6	3.2	188.7	(68.9-410.8)	Female	14	16.9	83.1	(45.4-139.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.5	nc	(nc-nc)	Male	145	112.2	129.2	(109.1-152.1)
Female	9	3.3	276.6	(126.2-525.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	8.7	184.3	(105.3-299.3)
Male	26	20.8	125.1	(81.7-183.3)	Female	2	6.7	nc	(nc-nc)
Female	17	14.4	118.2	(68.8-189.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.9	87.1	(31.8-189.7)
Male	4	5.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	11	10.4	106.2	(52.9-190.0)
<u>Leukemia</u>					Female	45	35.3	127.6	(93.0-170.7)
Male	16	15.0	106.5	(60.8-173.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	13.7	117.0	(66.9-190.1)	Female	44	40.4	109.0	(79.2-146.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	12.8	109.5	(59.8-183.8)	Male	566	470.9	120.2	(110.5-130.5)
Female	2	5.5	nc	(nc-nc)	Female	613	615.3	99.6	(91.9-107.8)
<u>Lung and Bronchus</u>									
Male	74	62.1	119.1	(93.5-149.5)					
Female	98	84.7	115.7	(93.9-141.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	9.9	121.2	(62.5-211.7)	Male	10	6.5	154.3	(73.9-283.8)
Female	4	3.2	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	5.8	102.7	(37.5-223.6)
Female	47	40.7	115.4	(84.8-153.4)	Female	8	4.6	172.8	(74.4-340.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	14	5.2	270.7	(147.9-454.2)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	15	10.8	138.3	(77.3-228.1)	<u>Ovary</u>				
Female	15	9.1	164.9	(92.2-271.9)	Female	7	3.4	205.7	(82.4-423.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	5	3.7	135.4	(43.6-315.9)
Female	1	0.7	nc	(nc-nc)	Female	6	3.2	187.1	(68.3-407.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	36.2	77.3	(51.3-111.7)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	8	6.0	133.7	(57.6-263.5)	Female	1	1.2	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	109.2	(47.0-215.1)
Male	3	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	11	9.5	116.4	(58.0-208.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.7	nc	(nc-nc)	Male	139	136.2	102.0	(85.8-120.5)
Female	1	1.1	nc	(nc-nc)	Female	167	128.8	129.6	(110.7-150.9)
<u>Lung and Bronchus</u>									
Male	21	18.4	114.0	(70.5-174.3)					
Female	28	17.6	159.3	(105.8-230.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	22.2	54.1	(27.9-94.5)
Female	0	0.1	nc	(nc-nc)	Female	9	13.2	68.1	(31.1-129.3)
<u>Lung and Bronchus</u>									
Male	2	3.4	nc	(nc-nc)					
Female	3	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	24.3	131.8	(90.1-186.0)	Male	19	15.5	122.9	(74.0-192.0)
Female	8	8.3	96.3	(41.5-189.7)	Female	15	11.7	128.4	(71.8-211.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	4.6	218.0	(104.4-401.0)	Male	4	5.1	nc	(nc-nc)
Female	6	3.8	159.4	(58.2-346.9)	Female	1	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	17	13.8	123.1	(71.7-197.1)
Female	116	97.4	119.0	(98.4-142.8)	Female	13	11.9	109.2	(58.1-186.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	10	11.9	83.7	(40.1-154.0)
<u>Colon / Rectum</u>					Female	8	5.1	157.1	(67.7-309.6)
Male	19	26.3	72.3	(43.5-113.0)	<u>Ovary</u>				
Female	20	24.1	83.0	(50.7-128.1)	Female	9	8.4	107.5	(49.1-204.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.5	77.4	(24.9-180.6)	Male	14	8.8	159.3	(87.0-267.3)
Female	3	1.7	nc	(nc-nc)	Female	10	8.4	119.4	(57.1-219.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	94	80.3	117.1	(94.7-143.3)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.9	101.9	(37.2-221.7)
Male	10	13.8	72.5	(34.7-133.3)	Female	4	3.3	nc	(nc-nc)
Female	7	7.6	91.8	(36.8-189.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.7	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	17.2	64.0	(31.9-114.5)
Male	10	9.7	102.8	(49.2-189.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.7	nc	(nc-nc)	Female	24	22.5	106.6	(68.3-158.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.8	67.9	(24.8-147.9)	Male	331	319.0	103.8	(92.9-115.6)
Female	1	2.8	nc	(nc-nc)	Female	333	320.1	104.0	(93.2-115.8)
<u>Lung and Bronchus</u>									
Male	30	44.0	68.1	(46.0-97.3)					
Female	44	44.9	98.0	(71.2-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	31.0	154.6	(114.0-205.0)	Male	18	20.0	90.1	(53.4-142.4)
Female	20	13.2	151.8	(92.7-234.4)	Female	20	17.4	115.1	(70.3-177.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.8	85.7	(27.6-200.1)	Male	6	6.5	91.8	(33.5-199.9)
Female	8	5.5	146.0	(62.9-287.8)	Female	5	6.0	83.2	(26.8-194.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	29	17.9	161.7	(108.3-232.3)
Female	147	143.8	102.2	(86.4-120.1)	Female	25	18.3	136.9	(88.6-202.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.5	nc	(nc-nc)	Male	19	14.8	128.6	(77.4-200.9)
<u>Colon / Rectum</u>					Female	6	7.7	78.2	(28.6-170.3)
Male	48	33.5	143.5	(105.8-190.2)	<u>Ovary</u>				
Female	32	37.8	84.6	(57.9-119.5)	Female	5	12.4	40.5	(13.0-94.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.1	161.3	(85.8-275.8)	Male	15	11.2	134.0	(74.9-221.0)
Female	4	2.6	nc	(nc-nc)	Female	15	13.4	112.1	(62.7-185.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	79	96.8	81.6	(64.6-101.7)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.6	79.3	(28.9-172.5)
Male	26	17.4	149.1	(97.4-218.5)	Female	2	5.1	nc	(nc-nc)
Female	8	11.5	69.6	(30.0-137.2)	<u>Testis</u>				
<u>Larynx</u>					Male	9	3.9	230.4	(105.1-437.4)
Male	7	4.8	145.9	(58.4-300.5)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	11	7.8	140.4	(70.0-251.2)
<u>Leukemia</u>					Female	20	24.4	82.1	(50.1-126.8)
Male	17	12.4	137.3	(79.9-219.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	10.3	nc	(nc-nc)	Female	28	32.8	85.3	(56.7-123.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	11.0	155.1	(90.3-248.3)	Male	485	402.1	120.6	(110.1-131.8)
Female	5	4.3	115.8	(37.3-270.2)	Female	490	483.0	101.4	(92.7-110.8)
<u>Lung and Bronchus</u>									
Male	66	56.0	117.8	(91.1-149.9)					
Female	88	69.8	126.1	(101.1-155.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	12.1	58.0	(23.2-119.4)
Female	0	0.1	nc	(nc-nc)	Female	10	9.6	103.7	(49.6-190.6)
<u>Lung and Bronchus</u>									
Male	2	1.6	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.9	91.6	(56.7-140.1)	Male	40	14.2	281.8	(201.3-383.7)
Female	12	8.0	149.5	(77.2-261.2)	Female	29	10.7	271.7	(181.9-390.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.1	146.3	(53.4-318.4)	Male	7	4.6	151.2	(60.6-311.5)
Female	3	3.5	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	6	12.7	47.3	(17.3-103.0)
Female	89	89.5	99.4	(79.8-122.4)	Female	9	11.2	80.6	(36.8-153.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.8	nc	(nc-nc)	Male	9	10.6	84.8	(38.7-161.0)
<u>Colon / Rectum</u>					Female	7	4.7	147.6	(59.1-304.2)
Male	21	24.4	86.0	(53.2-131.5)	<u>Ovary</u>				
Female	20	23.6	84.7	(51.7-130.8)	Female	8	7.6	104.7	(45.1-206.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.8	120.0	(48.1-247.3)	Male	7	8.1	86.5	(34.7-178.2)
Female	1	1.5	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.4	nc	(nc-nc)	Male	66	69.5	94.9	(73.4-120.8)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.5	110.0	(40.1-239.3)
Male	7	12.3	56.7	(22.7-116.9)	Female	4	3.2	nc	(nc-nc)
Female	6	7.0	85.2	(31.1-185.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.0	nc	(nc-nc)	Male	1	5.2	nc	(nc-nc)
<u>Leukemia</u>					Female	18	15.2	118.6	(70.2-187.4)
Male	10	9.0	110.7	(53.0-203.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.4	109.4	(43.8-225.5)	Female	21	20.0	104.9	(64.9-160.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	7.9	101.7	(43.8-200.3)	Male	291	288.6	100.8	(89.6-113.1)
Female	3	2.7	nc	(nc-nc)	Female	316	297.8	106.1	(94.7-118.5)
<u>Lung and Bronchus</u>									
Male	33	40.4	81.6	(56.2-114.7)					
Female	45	41.9	107.4	(78.3-143.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	17.9	61.3	(30.6-109.7)	Male	6	11.5	52.3	(19.1-113.8)
Female	2	5.4	nc	(nc-nc)	Female	8	7.9	101.6	(43.7-200.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	10.2	147.5	(82.5-243.2)
Female	37	65.6	56.4	(39.7-77.7)	Female	5	7.8	63.7	(20.5-148.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	3	8.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	3.4	148.3	(47.8-346.0)
Male	12	19.1	62.9	(32.5-110.0)	<u>Ovary</u>				
Female	9	15.7	57.2	(26.1-108.6)	Female	6	5.6	107.6	(39.3-234.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	4.8	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	7	5.4	129.7	(52.0-267.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	35	58.5	59.8	(41.7-83.2)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.3	nc	(nc-nc)
Male	5	10.2	49.1	(15.8-114.5)	Female	1	2.2	nc	(nc-nc)
Female	0	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.0	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	8	12.1	66.3	(28.5-130.6)
Male	6	7.1	84.8	(31.0-184.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.4	nc	(nc-nc)	Female	8	15.0	53.4	(23.0-105.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.4	nc	(nc-nc)	Male	141	234.4	60.2	(50.6-70.9)
Female	0	1.9	nc	(nc-nc)	Female	139	213.4	65.1	(54.8-76.9)
<u>Lung and Bronchus</u>									
Male	20	33.2	60.2	(36.7-92.9)					
Female	26	29.7	87.5	(57.2-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	18.8	58.4	(29.1-104.5)	Male	13	12.4	105.2	(56.0-179.9)
Female	7	6.1	115.5	(46.3-237.9)	Female	17	9.3	181.9	(105.9-291.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	6	4.0	149.4	(54.6-325.2)
Female	1	3.1	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	14	11.1	126.2	(68.9-211.7)
Female	88	78.4	112.3	(90.1-138.3)	Female	6	9.1	66.1	(24.1-143.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.7	nc	(nc-nc)	Male	6	9.9	60.4	(22.1-131.5)
<u>Colon / Rectum</u>					Female	1	4.0	nc	(nc-nc)
Male	11	21.4	51.4	(25.6-92.0)	<u>Ovary</u>				
Female	10	18.6	53.8	(25.8-99.0)	Female	5	6.6	76.0	(24.5-177.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.2	nc	(nc-nc)	Male	9	7.0	128.6	(58.7-244.2)
Female	2	1.2	nc	(nc-nc)	Female	8	6.2	129.3	(55.7-254.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	64	65.9	97.1	(74.7-124.0)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	7	11.4	61.6	(24.7-126.9)	Female	3	2.5	nc	(nc-nc)
Female	8	6.0	134.4	(57.9-264.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	9	5.1	177.7	(81.1-337.4)
<u>Leukemia</u>					Female	26	14.8	175.5	(114.6-257.1)
Male	6	7.7	77.5	(28.3-168.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.2	nc	(nc-nc)	Female	18	17.7	101.8	(60.3-161.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.2	nc	(nc-nc)	Male	217	256.2	84.7	(73.8-96.7)
Female	3	2.1	nc	(nc-nc)	Female	265	250.1	106.0	(93.6-119.5)
<u>Lung and Bronchus</u>									
Male	17	34.1	49.9	(29.0-79.8)					
Female	38	32.9	115.5	(81.7-158.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	97.2	(31.3-226.8)	Male	4	3.1	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	14	17.7	79.2	(43.3-132.9)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.3	220.8	(71.2-515.3)
<u>Colon / Rectum</u>					Female	3	0.9	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	21	16.1	130.4	(80.7-199.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.9	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	6	4.2	142.1	(51.9-309.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.7	nc	(nc-nc)	Male	60	64.1	93.6	(71.4-120.5)
Female	0	0.5	nc	(nc-nc)	Female	55	57.9	95.1	(71.6-123.8)
<u>Lung and Bronchus</u>									
Male	5	9.3	54.0	(17.4-126.1)					
Female	11	8.5	129.6	(64.6-232.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	11	11.7	94.0	(46.9-168.3)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.7	102.6	(49.1-188.7)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	7	2.7	255.4	(102.3-526.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	35	37.2	94.0	(65.4-130.7)
Female	0	0.4	nc	(nc-nc)	Female	45	39.6	113.5	(82.8-151.9)
<u>Lung and Bronchus</u>									
Male	3	5.2	nc	(nc-nc)					
Female	7	5.9	118.9	(47.6-245.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	5.4	183.8	(88.0-338.0)	Male	5	3.4	148.3	(47.8-346.1)
Female	2	1.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	18	19.5	92.3	(54.7-145.8)	Female	5	2.3	216.5	(69.8-505.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	8	5.8	137.2	(59.1-270.4)	<u>Ovary</u>				
Female	3	4.8	nc	(nc-nc)	Female	5	1.7	300.1	(96.7-700.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	17.3	80.7	(44.1-135.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.4	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	61	69.6	87.6	(67.0-112.6)
Female	0	0.6	nc	(nc-nc)	Female	54	63.4	85.2	(64.0-111.1)
<u>Lung and Bronchus</u>									
Male	5	9.7	51.8	(16.7-120.9)					
Female	5	8.9	56.4	(18.2-131.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	6.0	231.8	(126.6-389.0)	Male	2	4.8	nc	(nc-nc)
Female	6	2.0	292.8	(106.9-637.3)	Female	1	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.3	188.1	(81.0-370.7)
Female	28	25.6	109.2	(72.6-157.9)	Female	2	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.3	nc	(nc-nc)
Male	12	7.9	152.3	(78.6-266.0)	<u>Ovary</u>				
Female	7	5.9	117.8	(47.2-242.8)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	29	22.6	128.3	(85.9-184.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	7	4.5	156.1	(62.5-321.6)	Female	1	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.8	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	12	5.8	208.2	(107.5-363.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	2.7	259.6	(104.0-534.8)	Male	122	93.4	130.6	(108.4-155.9)
Female	0	0.7	nc	(nc-nc)	Female	91	82.4	110.5	(89.0-135.7)
<u>Lung and Bronchus</u>									
Male	17	11.3	150.0	(87.4-240.3)					
Female	10	11.4	87.7	(42.0-161.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	36.7	114.5	(82.5-154.8)	Male	18	23.7	76.0	(45.0-120.2)
Female	12	12.3	97.8	(50.5-170.9)	Female	22	17.8	123.7	(77.5-187.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.4	67.9	(21.9-158.4)	Male	10	7.6	131.0	(62.7-240.9)
Female	0	5.8	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.3	nc	(nc-nc)	Male	25	21.4	116.6	(75.5-172.2)
Female	165	144.7	114.0	(97.3-132.8)	Female	15	17.7	85.0	(47.5-140.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.1	98.7	(31.8-230.2)	Male	12	17.9	67.2	(34.7-117.4)
<u>Colon / Rectum</u>					Female	4	7.4	nc	(nc-nc)
Male	44	40.5	108.6	(78.9-145.8)	<u>Ovary</u>				
Female	32	36.9	86.8	(59.3-122.5)	Female	14	12.2	114.4	(62.5-192.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	9.5	83.9	(36.1-165.3)	Male	9	13.2	68.3	(31.2-129.7)
Female	6	2.4	247.7	(90.5-539.2)	Female	10	12.5	80.3	(38.4-147.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	128	115.8	110.6	(92.2-131.5)
Female	4	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	8.9	nc	(nc-nc)
Male	24	21.0	114.3	(73.2-170.1)	Female	6	5.0	119.3	(43.6-259.8)
Female	7	11.3	62.2	(24.9-128.1)	<u>Testis</u>				
<u>Larynx</u>					Male	4	5.2	nc	(nc-nc)
Male	2	5.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	16	9.7	164.5	(94.0-267.1)
<u>Leukemia</u>					Female	19	28.0	67.8	(40.8-105.8)
Male	12	15.2	78.9	(40.7-137.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.3	106.6	(53.1-190.8)	Female	31	31.1	99.6	(67.7-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	12.9	100.9	(53.6-172.5)	Male	492	480.1	102.5	(93.6-112.0)
Female	3	4.0	nc	(nc-nc)	Female	475	477.1	99.6	(90.8-108.9)
<u>Lung and Bronchus</u>									
Male	63	65.0	96.9	(74.5-124.0)					
Female	66	65.1	101.4	(78.4-129.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	8	9.0	88.5	(38.1-174.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	6.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	24.4	45.1	(22.5-80.8)
Female	0	0.3	nc	(nc-nc)	Female	22	28.6	76.8	(48.1-116.3)
<u>Lung and Bronchus</u>									
Male	0	3.0	nc	(nc-nc)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	26.2	122.1	(83.5-172.4)	Male	7	15.7	44.5	(17.8-91.8)
Female	13	10.0	130.3	(69.3-222.9)	Female	10	11.9	83.9	(40.2-154.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.4	113.6	(36.6-265.2)	Male	0	5.1	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	6	4.4	137.1	(50.1-298.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	13	14.1	92.5	(49.2-158.2)
Female	79	98.0	80.6	(63.8-100.4)	Female	16	13.2	121.6	(69.5-197.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	8	11.2	71.5	(30.8-140.9)
<u>Colon / Rectum</u>					Female	7	5.4	129.5	(51.9-266.9)
Male	28	26.9	104.1	(69.1-150.4)	<u>Ovary</u>				
Female	34	28.1	121.0	(83.8-169.0)	Female	7	8.5	82.4	(33.0-169.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.4	109.4	(43.8-225.3)	Male	10	9.0	110.7	(53.0-203.6)
Female	0	1.9	nc	(nc-nc)	Female	15	10.2	147.2	(82.3-242.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.6	nc	(nc-nc)	Male	73	76.2	95.9	(75.1-120.5)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	6.1	163.7	(78.4-301.0)
Male	13	13.3	97.6	(51.9-166.9)	Female	5	3.8	130.1	(41.9-303.5)
Female	6	8.1	74.3	(27.1-161.7)	<u>Testis</u>				
<u>Larynx</u>					Male	6	2.6	232.8	(85.0-506.6)
Male	4	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Leukemia</u>					Female	20	15.5	128.9	(78.7-199.1)
Male	13	10.0	130.3	(69.3-222.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	7.5	133.7	(64.0-246.0)	Female	14	21.7	64.5	(35.2-108.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.3	nc	(nc-nc)	Male	320	319.3	100.2	(89.5-111.8)
Female	0	3.1	nc	(nc-nc)	Female	314	341.1	92.0	(82.1-102.8)
<u>Lung and Bronchus</u>									
Male	48	46.0	104.3	(76.9-138.3)					
Female	38	51.7	73.4	(52.0-100.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	50.5	67.4	(46.7-94.2)	Male	27	36.0	74.9	(49.4-109.0)
Female	17	19.0	89.3	(52.0-143.1)	Female	20	33.0	60.6	(37.0-93.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	13.0	69.1	(31.5-131.2)	Male	10	10.7	93.8	(44.9-172.5)
Female	11	10.2	108.0	(53.8-193.2)	Female	12	8.8	136.1	(70.3-237.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	35	32.4	107.9	(75.2-150.1)
Female	185	226.2	81.8	(70.4-94.5)	Female	21	28.8	73.0	(45.2-111.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	10.0	109.9	(54.8-196.6)	Male	21	25.4	82.7	(51.2-126.4)
<u>Colon / Rectum</u>					Female	12	11.9	101.2	(52.3-176.9)
Male	51	57.6	88.6	(65.9-116.4)	<u>Ovary</u>				
Female	45	57.7	78.0	(56.9-104.4)	Female	24	19.9	120.4	(77.1-179.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	13.0	100.2	(53.3-171.4)	Male	18	18.2	98.9	(58.6-156.3)
Female	3	3.7	nc	(nc-nc)	Female	19	19.3	98.6	(59.3-154.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	7.9	114.0	(52.0-216.5)	Male	137	152.6	89.8	(75.4-106.1)
Female	4	6.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	12.7	126.3	(72.1-205.1)
Male	35	30.5	114.7	(79.9-159.6)	Female	14	7.8	179.0	(97.8-300.4)
Female	22	17.9	123.1	(77.1-186.3)	<u>Testis</u>				
<u>Larynx</u>					Male	11	17.7	62.3	(31.1-111.5)
Male	9	7.6	117.9	(53.8-223.8)	<u>Thyroid</u>				
Female	3	2.3	nc	(nc-nc)	Male	21	18.0	116.5	(72.1-178.1)
<u>Leukemia</u>					Female	45	58.9	76.4	(55.7-102.2)
Male	17	23.3	72.9	(42.4-116.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	17.6	96.3	(56.1-154.3)	Female	49	48.6	100.9	(74.6-133.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	26	17.9	145.4	(94.9-213.0)	Male	664	693.2	95.8	(88.6-103.4)
Female	14	6.4	220.0	(120.2-369.1)	Female	705	774.7	91.0	(84.4-98.0)
<u>Lung and Bronchus</u>									
Male	115	88.8	129.5	(106.9-155.4)					
Female	98	99.7	98.3	(79.8-119.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	20.1	64.7	(34.4-110.6)	Male	15	12.5	120.3	(67.3-198.4)
Female	12	8.0	149.7	(77.3-261.6)	Female	12	10.5	114.1	(58.9-199.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.1	81.2	(37.0-154.1)
Female	96	84.1	114.2	(92.5-139.4)	Female	12	10.9	109.6	(56.6-191.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.6	189.0	(60.9-441.1)	Male	7	9.1	77.3	(31.0-159.2)
<u>Colon / Rectum</u>					Female	5	4.6	109.2	(35.2-254.7)
Male	22	21.0	104.8	(65.7-158.7)	<u>Ovary</u>				
Female	32	22.8	140.3	(95.9-198.0)	Female	6	7.4	81.4	(29.7-177.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.1	nc	(nc-nc)	Male	2	7.1	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	9	8.1	111.3	(50.8-211.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	54	60.9	88.6	(66.6-115.7)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.8	104.6	(33.7-244.0)
Male	8	10.7	75.0	(32.3-147.8)	Female	1	3.1	nc	(nc-nc)
Female	8	6.9	116.1	(50.0-228.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	14	15.4	91.2	(49.8-153.0)
Male	5	7.8	64.5	(20.8-150.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.5	123.5	(53.2-243.4)	Female	29	18.9	153.2	(102.6-220.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.8	nc	(nc-nc)	Male	220	252.1	87.3	(76.1-99.6)
Female	0	2.6	nc	(nc-nc)	Female	314	289.7	108.4	(96.7-121.1)
<u>Lung and Bronchus</u>									
Male	35	35.8	97.9	(68.2-136.1)					
Female	36	42.2	85.4	(59.8-118.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.1	74.2	(27.1-161.5)	Male	0	4.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
Female	24	27.3	88.0	(56.4-130.9)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	8	8.4	95.4	(41.1-188.0)	<u>Ovary</u>				
Female	6	6.4	93.8	(34.3-204.2)	Female	1	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	20	24.0	83.2	(50.8-128.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.9	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.1	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	7	6.2	112.2	(45.0-231.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.6	nc	(nc-nc)	Male	73	99.4	73.5	(57.6-92.4)
Female	0	0.8	nc	(nc-nc)	Female	78	88.0	88.7	(70.1-110.6)
<u>Lung and Bronchus</u>									
Male	7	13.6	51.4	(20.6-105.8)					
Female	16	12.2	131.2	(75.0-213.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.4	95.8	(43.7-182.0)	Male	9	6.3	142.4	(65.0-270.3)
Female	5	3.2	155.9	(50.2-363.7)	Female	3	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.6	nc	(nc-nc)
Female	46	40.3	114.2	(83.6-152.3)	Female	4	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	5	5.1	98.8	(31.8-230.5)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	6	10.9	54.8	(20.0-119.4)	<u>Ovary</u>				
Female	9	9.9	91.3	(41.7-173.3)	Female	1	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	28	31.6	88.5	(58.8-128.0)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.4	nc	(nc-nc)
Male	10	5.7	175.0	(83.8-321.8)	Female	1	1.3	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.8	76.9	(28.1-167.4)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	6	8.7	68.9	(25.1-149.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.6	nc	(nc-nc)	Male	125	128.0	97.7	(81.3-116.4)
Female	0	1.1	nc	(nc-nc)	Female	115	130.0	88.5	(73.0-106.2)
<u>Lung and Bronchus</u>									
Male	14	16.6	84.3	(46.0-141.4)					
Female	12	17.3	69.2	(35.7-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	16.1	105.7	(61.5-169.2)	Male	6	10.4	57.5	(21.0-125.2)
Female	7	6.9	101.4	(40.6-209.0)	Female	4	9.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	6	3.3	184.3	(67.3-401.2)
Female	2	3.0	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	9.4	117.2	(58.4-209.7)
Female	58	72.6	79.9	(60.7-103.3)	Female	14	9.5	146.6	(80.1-246.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	8	7.7	103.7	(44.7-204.4)
<u>Colon / Rectum</u>					Female	0	4.0	nc	(nc-nc)
Male	20	17.8	112.4	(68.6-173.6)	<u>Ovary</u>				
Female	20	20.3	98.8	(60.3-152.5)	Female	10	6.4	157.4	(75.4-289.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.1	nc	(nc-nc)	Male	8	5.8	139.0	(59.9-273.9)
Female	0	1.3	nc	(nc-nc)	Female	2	7.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	52	48.3	107.7	(80.5-141.3)
Female	4	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.9	153.3	(56.0-333.7)
Male	8	9.0	88.6	(38.2-174.7)	Female	4	2.8	nc	(nc-nc)
Female	10	5.8	171.8	(82.3-316.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	7	2.4	297.9	(119.3-613.7)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	10	13.1	76.2	(36.5-140.2)
Male	7	6.8	102.8	(41.2-211.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.6	177.7	(85.1-326.8)	Female	19	16.4	116.0	(69.8-181.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	5.6	142.3	(61.3-280.3)	Male	245	208.0	117.8	(103.5-133.5)
Female	0	2.3	nc	(nc-nc)	Female	231	249.5	92.6	(81.0-105.3)
<u>Lung and Bronchus</u>									
Male	49	28.1	174.5	(129.1-230.7)					
Female	26	34.7	75.0	(49.0-109.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.3	116.4	(60.1-203.3)	Male	6	6.7	89.5	(32.7-194.7)
Female	2	4.2	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	45	44.9	100.3	(73.2-134.3)	Female	6	5.8	102.7	(37.5-223.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	5	5.1	98.2	(31.6-229.2)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	7	11.5	61.0	(24.4-125.7)	<u>Ovary</u>				
Female	15	12.5	120.0	(67.1-197.9)	Female	3	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	30	32.9	91.3	(61.6-130.3)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.5	nc	(nc-nc)
Male	10	5.9	168.3	(80.6-309.6)	Female	2	1.7	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.9	76.4	(27.9-166.3)
Male	2	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.3	149.5	(48.2-348.8)	Female	9	9.9	91.2	(41.6-173.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.7	nc	(nc-nc)	Male	122	135.7	89.9	(74.6-107.3)
Female	3	1.4	nc	(nc-nc)	Female	128	152.7	83.8	(69.9-99.7)
<u>Lung and Bronchus</u>									
Male	19	18.3	104.0	(62.6-162.4)					
Female	14	21.5	65.2	(35.6-109.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	11.9	184.7	(115.7-279.7)	Male	12	8.1	148.1	(76.5-258.8)
Female	11	4.2	262.6	(130.9-469.8)	Female	5	6.0	83.3	(26.9-194.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	6	1.9	308.7	(112.7-671.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.2	83.2	(30.4-181.1)
Female	45	49.2	91.4	(66.7-122.3)	Female	9	6.0	150.1	(68.5-284.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	11	6.5	168.3	(83.9-301.2)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	9	13.3	67.5	(30.8-128.1)	<u>Ovary</u>				
Female	12	12.1	99.5	(51.4-173.9)	Female	1	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.4	147.0	(47.4-343.1)	Male	5	4.5	112.1	(36.1-261.6)
Female	1	0.8	nc	(nc-nc)	Female	5	4.2	117.7	(37.9-274.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	35	43.6	80.2	(55.9-111.5)
Female	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	10	7.5	133.0	(63.7-244.7)	Female	2	1.7	nc	(nc-nc)
Female	6	3.8	157.0	(57.3-341.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.2	98.3	(44.9-186.7)
Male	11	5.1	216.4	(107.9-387.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.5	nc	(nc-nc)	Female	17	11.2	152.2	(88.6-243.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.7	127.6	(46.6-277.7)	Male	188	167.6	112.2	(96.7-129.4)
Female	2	1.4	nc	(nc-nc)	Female	182	162.0	112.3	(96.6-129.9)
<u>Lung and Bronchus</u>									
Male	34	22.2	153.5	(106.3-214.5)					
Female	25	22.4	111.7	(72.3-164.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	118.9	73.1	(58.6-90.2)	Male	28	78.8	35.5	(23.6-51.3)
Female	40	47.2	84.7	(60.5-115.3)	Female	26	71.0	36.6	(23.9-53.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	31	27.0	114.6	(77.9-162.7)	Male	22	24.9	88.2	(55.3-133.6)
Female	21	24.1	87.1	(53.9-133.1)	Female	29	21.8	133.0	(89.0-191.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	7	4.2	166.7	(66.8-343.4)	Male	76	71.5	106.3	(83.7-133.0)
Female	512	552.9	92.6	(84.8-101.0)	Female	67	68.6	97.6	(75.7-124.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	42	20.0	210.2	(151.5-284.2)	Male	71	59.5	119.3	(93.2-150.5)
<u>Colon / Rectum</u>					Female	20	29.1	68.8	(42.0-106.3)
Male	142	132.2	107.4	(90.5-126.6)	<u>Ovary</u>				
Female	155	140.0	110.7	(94.0-129.6)	Female	40	47.8	83.6	(59.7-113.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	33	31.4	105.2	(72.4-147.8)	Male	48	43.0	111.7	(82.4-148.1)
Female	8	9.3	85.9	(37.0-169.2)	Female	51	47.8	106.6	(79.4-140.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	14	12.1	115.5	(63.1-193.8)	Male	328	384.0	85.4	(76.4-95.2)
Female	15	10.8	138.8	(77.6-228.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	35	29.2	119.9	(83.5-166.8)
Male	84	69.9	120.2	(95.9-148.8)	Female	21	19.0	110.4	(68.3-168.8)
Female	55	43.7	125.8	(94.8-163.8)	<u>Testis</u>				
<u>Larynx</u>					Male	12	22.6	53.0	(27.4-92.6)
Male	17	18.3	92.9	(54.1-148.7)	<u>Thyroid</u>				
Female	10	6.0	166.5	(79.7-306.3)	Male	15	34.2	43.9	(24.5-72.4)
<u>Leukemia</u>					Female	78	114.0	68.4	(54.1-85.4)
Male	49	52.5	93.3	(69.0-123.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	39	41.7	93.6	(66.6-128.0)	Female	115	123.1	93.5	(77.2-112.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	61	43.2	141.3	(108.1-181.5)	Male	1530	1599.2	95.7	(90.9-100.6)
Female	14	16.0	87.6	(47.8-146.9)	Female	1763	1851.6	95.2	(90.8-99.8)
<u>Lung and Bronchus</u>									
Male	240	212.5	112.9	(99.1-128.2)					
Female	252	250.3	100.7	(88.6-113.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.2	152.7	(76.1-273.2)	Male	8	5.0	161.0	(69.3-317.2)
Female	4	2.8	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.5	176.0	(75.8-346.8)
Female	41	35.4	115.8	(83.1-157.1)	Female	1	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	8	8.8	90.9	(39.2-179.2)	<u>Ovary</u>				
Female	2	8.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.1	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	42	27.8	150.9	(108.7-204.0)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	8	4.9	164.6	(70.9-324.3)	Female	2	1.2	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.7	104.1	(41.7-214.4)
Male	6	3.2	189.9	(69.3-413.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.4	nc	(nc-nc)	Female	10	7.6	130.8	(62.6-240.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	130	104.8	124.0	(103.6-147.2)
Female	0	0.9	nc	(nc-nc)	Female	112	114.0	98.3	(80.9-118.3)
<u>Lung and Bronchus</u>									
Male	10	13.2	75.9	(36.4-139.7)					
Female	18	14.6	123.1	(72.9-194.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.6	nc	(nc-nc)	Male	7	2.1	327.5	(131.2-674.8)
Female	1	1.5	nc	(nc-nc)	Female	6	1.6	372.7	(136.1-811.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	10	12.9	77.3	(37.0-142.2)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.1	170.7	(68.4-351.6)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	10.2	118.0	(60.9-206.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	7	2.9	243.7	(97.6-502.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	43.2	92.5	(66.1-126.0)
Female	0	0.4	nc	(nc-nc)	Female	48	47.6	100.8	(74.3-133.7)
<u>Lung and Bronchus</u>									
Male	1	6.5	nc	(nc-nc)					
Female	2	7.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	28.7	83.7	(53.6-124.6)	Male	12	17.4	68.8	(35.5-120.2)
Female	10	10.1	98.7	(47.2-181.5)	Female	10	13.5	73.9	(35.4-135.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.9	122.3	(44.7-266.2)	Male	7	5.7	122.9	(49.3-253.3)
Female	4	4.3	nc	(nc-nc)	Female	9	4.6	196.4	(89.6-372.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	17	15.6	109.0	(63.5-174.5)
Female	137	108.9	125.9	(105.7-148.8)	Female	13	14.0	92.9	(49.4-158.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.5	nc	(nc-nc)	Male	17	12.7	133.6	(77.8-213.9)
<u>Colon / Rectum</u>					Female	6	5.9	101.6	(37.1-221.1)
Male	36	30.0	120.2	(84.2-166.4)	<u>Ovary</u>				
Female	28	29.4	95.3	(63.3-137.7)	Female	14	9.5	148.1	(80.9-248.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.2	69.6	(22.4-162.3)	Male	6	10.0	60.3	(22.0-131.2)
Female	0	2.0	nc	(nc-nc)	Female	14	10.4	135.1	(73.8-226.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	51	86.3	59.1	(44.0-77.7)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	6.7	148.5	(71.1-273.0)
Male	13	15.0	86.7	(46.1-148.3)	Female	5	4.0	124.0	(40.0-289.4)
Female	9	8.7	103.4	(47.2-196.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.0	167.2	(53.9-390.3)
Male	3	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	1.2	nc	(nc-nc)	Male	10	6.4	157.1	(75.2-288.9)
<u>Leukemia</u>					Female	26	19.1	136.0	(88.8-199.3)
Male	17	11.0	154.9	(90.2-248.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.0	124.3	(59.5-228.5)	Female	36	24.7	145.5	(101.9-201.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.4	74.5	(29.9-153.6)	Male	332	355.8	93.3	(83.5-103.9)
Female	9	3.3	270.4	(123.4-513.4)	Female	427	369.6	115.5	(104.8-127.0)
<u>Lung and Bronchus</u>									
Male	41	50.2	81.6	(58.6-110.8)					
Female	54	52.4	103.1	(77.4-134.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	32.7	94.9	(64.5-134.7)	Male	16	20.4	78.5	(44.8-127.5)
Female	17	13.1	130.2	(75.8-208.4)	Female	23	17.2	133.5	(84.6-200.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.0	nc	(nc-nc)	Male	9	6.7	135.3	(61.7-256.8)
Female	6	5.5	109.9	(40.1-239.2)	Female	7	5.9	118.1	(47.3-243.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	15	18.3	81.8	(45.7-134.9)
Female	133	139.9	95.1	(79.6-112.7)	Female	26	18.0	144.2	(94.1-211.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.5	nc	(nc-nc)	Male	11	15.1	72.9	(36.3-130.4)
<u>Colon / Rectum</u>					Female	3	7.6	nc	(nc-nc)
Male	35	34.5	101.5	(70.7-141.1)	<u>Ovary</u>				
Female	39	37.9	102.9	(73.2-140.7)	Female	14	12.1	115.5	(63.1-193.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	8.4	130.9	(65.3-234.3)	Male	13	11.6	111.9	(59.5-191.4)
Female	5	2.6	195.5	(63.0-456.3)	Female	20	13.4	149.2	(91.1-230.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	97	103.5	93.7	(76.0-114.3)
Female	6	1.9	316.2	(115.5-688.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.8	115.2	(52.6-218.6)
Male	25	17.8	140.5	(90.9-207.4)	Female	6	5.2	116.2	(42.4-252.8)
Female	17	11.2	151.8	(88.4-243.1)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.9	152.5	(55.7-332.0)
Male	9	4.9	183.7	(83.8-348.7)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	9	7.8	115.9	(52.9-220.0)
<u>Leukemia</u>					Female	27	24.2	111.4	(73.4-162.0)
Male	12	12.9	92.8	(47.9-162.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	10.4	77.2	(33.2-152.1)	Female	22	31.9	69.0	(43.2-104.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	11.2	107.0	(55.2-187.0)	Male	429	418.5	102.5	(93.0-112.7)
Female	2	4.3	nc	(nc-nc)	Female	494	475.1	104.0	(95.0-113.6)
<u>Lung and Bronchus</u>									
Male	62	58.2	106.5	(81.7-136.6)					
Female	59	67.5	87.4	(66.6-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	8.2	195.3	(111.6-317.3)	Male	4	5.2	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	28	30.0	93.3	(62.0-134.9)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	9	9.0	100.2	(45.7-190.2)	<u>Ovary</u>				
Female	8	6.7	119.7	(51.5-235.9)	Female	5	2.5	200.1	(64.5-466.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	30	26.0	115.4	(77.8-164.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.5	127.1	(50.9-261.8)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	9	7.0	128.9	(58.8-244.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.9	nc	(nc-nc)	Male	96	106.1	90.5	(73.3-110.5)
Female	0	0.8	nc	(nc-nc)	Female	103	94.8	108.7	(88.7-131.8)
<u>Lung and Bronchus</u>									
Male	7	14.5	48.2	(19.3-99.2)					
Female	10	12.8	78.0	(37.4-143.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	10.6	160.2	(93.3-256.5)	Male	9	6.8	132.3	(60.4-251.2)
Female	5	3.7	134.6	(43.4-314.1)	Female	8	5.2	153.1	(65.9-301.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.1	132.0	(56.9-260.2)
Female	38	43.0	88.4	(62.5-121.3)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.2	95.8	(30.9-223.6)
<u>Colon / Rectum</u>					Female	2	2.3	nc	(nc-nc)
Male	8	11.5	69.5	(29.9-136.9)	<u>Ovary</u>				
Female	10	10.9	91.9	(44.0-169.0)	Female	2	3.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.8	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	7	3.8	183.8	(73.6-378.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.7	nc	(nc-nc)	Male	39	35.4	110.2	(78.3-150.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	6	6.1	98.6	(36.0-214.6)	Female	1	1.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	7.9	63.2	(20.4-147.4)
Male	5	4.3	116.3	(37.5-271.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	18	9.6	187.0	(110.8-295.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.9	nc	(nc-nc)	Male	151	140.1	107.8	(91.3-126.4)
Female	2	1.2	nc	(nc-nc)	Female	135	142.2	95.0	(79.6-112.4)
<u>Lung and Bronchus</u>									
Male	21	19.4	108.3	(67.0-165.5)					
Female	14	19.8	70.8	(38.7-118.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.2	73.0	(39.9-122.5)	Male	17	12.8	133.1	(77.5-213.1)
Female	1	6.3	nc	(nc-nc)	Female	9	9.3	96.6	(44.1-183.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.0	175.2	(70.2-361.0)	Male	5	4.2	119.9	(38.6-279.8)
Female	5	3.1	163.8	(52.8-382.2)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	11.4	61.5	(24.6-126.7)
Female	118	79.4	148.6	(123.0-178.0)	Female	14	9.3	151.2	(82.6-253.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	4	10.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	4.0	124.5	(40.1-290.5)
Male	27	21.5	125.6	(82.7-182.7)	<u>Ovary</u>				
Female	13	19.1	68.1	(36.2-116.5)	Female	9	6.7	135.2	(61.7-256.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	5.4	nc	(nc-nc)	Male	9	7.1	126.0	(57.5-239.2)
Female	2	1.3	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	67	68.3	98.1	(76.0-124.6)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.8	nc	(nc-nc)
Male	9	11.8	76.1	(34.7-144.4)	Female	3	2.6	nc	(nc-nc)
Female	6	6.0	99.3	(36.3-216.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	7	5.3	133.0	(53.3-274.1)
<u>Leukemia</u>					Female	19	14.4	132.2	(79.5-206.4)
Male	7	8.0	87.0	(34.8-179.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.3	95.0	(30.6-221.7)	Female	18	17.8	101.2	(59.9-160.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	7.4	67.1	(21.6-156.7)	Male	223	264.5	84.3	(73.6-96.1)
Female	1	2.2	nc	(nc-nc)	Female	292	253.8	115.0	(102.2-129.0)
<u>Lung and Bronchus</u>									
Male	13	35.8	36.3	(19.3-62.1)					
Female	29	34.0	85.4	(57.2-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.2	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	17	10.4	163.1	(95.0-261.2)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	10.4	77.2	(33.3-152.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	32	42.8	74.7	(51.1-105.5)
Female	0	0.3	nc	(nc-nc)	Female	34	34.7	97.9	(67.8-136.8)
<u>Lung and Bronchus</u>									
Male	3	5.5	nc	(nc-nc)					
Female	3	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.0	130.2	(69.2-222.6)	Male	10	6.5	152.8	(73.1-281.0)
Female	5	2.5	196.8	(63.4-459.2)	Female	7	4.3	161.6	(64.7-333.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	5.9	152.3	(69.5-289.2)
Female	38	36.6	103.7	(73.4-142.4)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.3	nc	(nc-nc)	Male	1	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	6	11.3	53.0	(19.4-115.4)	<u>Ovary</u>				
Female	8	7.8	103.0	(44.3-202.9)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.7	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	30	34.2	87.7	(59.2-125.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.5	nc	(nc-nc)
Male	9	6.1	147.8	(67.5-280.7)	Female	1	1.1	nc	(nc-nc)
Female	5	2.7	187.1	(60.3-436.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.1	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	6	2.7	222.5	(81.2-484.3)
<u>Leukemia</u>					Female	7	7.5	93.8	(37.6-193.3)
Male	8	4.1	193.0	(83.1-380.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.2	nc	(nc-nc)	Female	12	8.3	144.3	(74.5-252.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.7	nc	(nc-nc)	Male	141	135.1	104.4	(87.8-123.1)
Female	1	0.9	nc	(nc-nc)	Female	124	113.1	109.6	(91.2-130.7)
<u>Lung and Bronchus</u>									
Male	20	18.1	110.6	(67.5-170.8)					
Female	14	14.2	98.5	(53.8-165.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	16.9	171.4	(114.8-246.2)	Male	14	10.4	134.4	(73.4-225.5)
Female	13	6.2	208.7	(111.0-356.9)	Female	16	8.4	190.0	(108.5-308.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.4	149.5	(81.6-250.8)
Female	76	68.8	110.5	(87.1-138.3)	Female	12	8.7	138.2	(71.3-241.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	5	7.8	64.0	(20.6-149.4)
<u>Colon / Rectum</u>					Female	4	3.7	nc	(nc-nc)
Male	17	18.2	93.6	(54.5-149.9)	<u>Ovary</u>				
Female	19	18.2	104.2	(62.7-162.8)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.3	nc	(nc-nc)	Male	6	6.0	100.4	(36.7-218.5)
Female	2	1.2	nc	(nc-nc)	Female	5	6.4	78.6	(25.3-183.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	56	51.7	108.3	(81.8-140.7)
Female	4	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	10	9.1	109.8	(52.6-202.0)	Female	2	2.5	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	3.9	129.0	(41.6-301.1)
<u>Leukemia</u>					Female	20	12.1	165.2	(100.9-255.2)
Male	5	6.8	74.0	(23.9-172.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	4.9	222.5	(110.9-398.1)	Female	20	15.4	129.5	(79.1-200.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.8	nc	(nc-nc)	Male	225	213.2	105.5	(92.2-120.3)
Female	2	2.0	nc	(nc-nc)	Female	273	230.5	118.4	(104.8-133.3)
<u>Lung and Bronchus</u>									
Male	27	29.4	91.9	(60.5-133.7)					
Female	32	32.4	98.7	(67.5-139.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	18.8	111.9	(69.3-171.1)	Male	12	12.1	98.8	(51.0-172.5)
Female	12	7.4	162.7	(83.9-284.1)	Female	6	10.0	60.3	(22.0-131.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.6	194.3	(77.8-400.3)	Male	4	3.9	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	14	10.9	129.0	(70.4-216.4)
Female	65	84.2	77.2	(59.6-98.4)	Female	10	10.2	97.6	(46.7-179.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	6	9.3	64.5	(23.6-140.4)
<u>Colon / Rectum</u>					Female	4	4.4	nc	(nc-nc)
Male	20	20.2	98.8	(60.4-152.7)	<u>Ovary</u>				
Female	18	21.2	84.9	(50.3-134.2)	Female	4	7.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.0	nc	(nc-nc)	Male	8	6.8	116.8	(50.3-230.2)
Female	0	1.5	nc	(nc-nc)	Female	8	7.5	106.9	(46.0-210.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.3	nc	(nc-nc)	Male	81	64.0	126.6	(100.6-157.4)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.6	nc	(nc-nc)
Male	20	10.9	183.0	(111.7-282.6)	Female	5	2.9	174.3	(56.2-406.6)
Female	5	6.6	75.3	(24.3-175.8)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.3	216.8	(69.9-506.0)
Male	3	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	5	4.8	103.1	(33.2-240.7)
<u>Leukemia</u>					Female	12	14.4	83.2	(43.0-145.4)
Male	4	7.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.7	87.2	(28.1-203.4)	Female	14	18.9	74.1	(40.5-124.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.8	88.0	(32.2-191.6)	Male	286	250.3	114.3	(101.4-128.3)
Female	2	2.4	nc	(nc-nc)	Female	240	277.2	86.6	(76.0-98.3)
<u>Lung and Bronchus</u>									
Male	33	34.5	95.7	(65.9-134.4)					
Female	37	39.9	92.8	(65.3-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	55.1	94.4	(70.5-123.8)	Male	23	36.6	62.8	(39.8-94.2)
Female	27	21.8	123.8	(81.6-180.2)	Female	25	30.8	81.1	(52.5-119.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.5	104.6	(54.0-182.7)	Male	9	11.8	76.5	(34.9-145.2)
Female	9	9.9	91.3	(41.7-173.3)	Female	14	10.0	140.2	(76.6-235.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.0	252.5	(81.4-589.2)	Male	37	32.8	112.9	(79.5-155.6)
Female	241	246.5	97.8	(85.8-110.9)	Female	41	30.8	133.0	(95.4-180.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.5	94.6	(40.7-186.4)	Male	38	28.4	133.8	(94.7-183.7)
<u>Colon / Rectum</u>					Female	11	13.0	84.5	(42.1-151.1)
Male	69	61.1	112.9	(87.8-142.9)	<u>Ovary</u>				
Female	87	65.1	133.7	(107.1-165.0)	Female	15	21.1	71.0	(39.7-117.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	15.0	86.9	(46.2-148.5)	Male	17	20.2	84.0	(48.9-134.6)
Female	1	4.2	nc	(nc-nc)	Female	26	22.4	116.2	(75.9-170.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	4.6	172.2	(74.2-339.4)	Male	144	186.9	77.1	(65.0-90.7)
Female	7	3.8	183.8	(73.6-378.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	13.6	95.5	(50.8-163.3)
Male	36	33.0	109.0	(76.3-150.9)	Female	9	8.8	102.0	(46.6-193.7)
Female	19	19.4	97.8	(58.9-152.8)	<u>Testis</u>				
<u>Larynx</u>					Male	10	8.4	119.0	(57.0-218.8)
Male	15	8.8	170.2	(95.2-280.8)	<u>Thyroid</u>				
Female	6	2.7	224.9	(82.1-489.5)	Male	20	15.3	130.6	(79.7-201.7)
<u>Leukemia</u>					Female	65	46.4	140.0	(108.0-178.4)
Male	16	23.1	69.1	(39.5-112.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	18.1	77.3	(42.2-129.6)	Female	47	54.5	86.2	(63.3-114.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	20.6	97.0	(59.2-149.8)	Male	759	747.8	101.5	(94.4-109.0)
Female	7	7.2	97.5	(39.1-201.0)	Female	853	825.1	103.4	(96.6-110.6)
<u>Lung and Bronchus</u>									
Male	134	101.0	132.6	(111.1-157.1)					
Female	121	113.0	107.1	(88.8-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.9	90.7	(41.4-172.2)	Male	6	6.3	95.1	(34.7-207.0)
Female	3	3.0	nc	(nc-nc)	Female	1	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.9	270.2	(87.1-630.7)	Male	2	2.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	25	37.0	67.6	(43.7-99.8)	Female	4	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	9	10.9	82.2	(37.5-156.1)	<u>Ovary</u>				
Female	12	8.8	135.7	(70.1-237.1)	Female	5	3.1	160.0	(51.6-373.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	20	34.9	57.3	(35.0-88.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.4	nc	(nc-nc)
Male	9	5.8	154.6	(70.5-293.4)	Female	1	1.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.7	74.6	(24.1-174.2)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	10	8.3	120.1	(57.5-220.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.6	137.1	(44.2-320.0)	Male	108	133.0	81.2	(66.6-98.1)
Female	0	1.0	nc	(nc-nc)	Female	112	119.6	93.6	(77.1-112.6)
<u>Lung and Bronchus</u>									
Male	19	17.7	107.6	(64.7-168.0)					
Female	24	17.0	141.3	(90.5-210.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	32.1	124.6	(89.0-169.7)	Male	16	21.1	75.8	(43.3-123.2)
Female	13	12.6	103.3	(55.0-176.7)	Female	16	17.1	93.7	(53.5-152.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.4	141.1	(64.4-267.8)	Male	3	6.7	nc	(nc-nc)
Female	6	5.4	110.6	(40.4-240.7)	Female	5	5.7	87.9	(28.3-205.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	18	18.7	96.2	(57.0-152.1)
Female	143	139.8	102.3	(86.2-120.5)	Female	18	17.5	103.0	(61.0-162.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.5	176.8	(76.1-348.3)	Male	15	16.3	92.3	(51.6-152.2)
<u>Colon / Rectum</u>					Female	10	7.4	136.0	(65.1-250.1)
Male	34	35.6	95.5	(66.1-133.5)	<u>Ovary</u>				
Female	34	36.7	92.6	(64.2-129.5)	Female	16	12.0	133.7	(76.4-217.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.6	151.9	(80.8-259.7)	Male	15	11.7	128.1	(71.7-211.3)
Female	4	2.5	nc	(nc-nc)	Female	11	12.8	86.2	(43.0-154.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	101	106.2	95.1	(77.4-115.5)
Female	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.9	101.3	(43.6-199.7)
Male	29	18.8	154.4	(103.4-221.8)	Female	4	5.0	nc	(nc-nc)
Female	13	11.1	117.2	(62.3-200.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.4	114.5	(36.9-267.3)
Male	5	5.0	99.2	(32.0-231.4)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	9	8.6	105.0	(47.9-199.3)
<u>Leukemia</u>					Female	26	25.0	104.1	(68.0-152.5)
Male	23	13.1	175.5	(111.2-263.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	10.1	149.1	(83.4-246.0)	Female	26	30.8	84.4	(55.1-123.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	11.8	67.6	(29.1-133.3)	Male	456	428.6	106.4	(96.9-116.6)
Female	1	4.1	nc	(nc-nc)	Female	498	467.7	106.5	(97.3-116.2)
<u>Lung and Bronchus</u>									
Male	70	58.7	119.2	(92.9-150.6)					
Female	81	66.5	121.8	(96.7-151.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.4	146.4	(47.2-341.7)	Male	8	2.4	327.8	(141.1-645.9)
Female	0	1.5	nc	(nc-nc)	Female	7	2.2	313.3	(125.5-645.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	27	18.9	143.0	(94.2-208.0)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	5	1.3	384.2	(123.8-896.7)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	12.5	120.3	(67.3-198.5)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	0.9	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.5	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.4	nc	(nc-nc)	Male	61	49.3	123.6	(94.5-158.8)
Female	0	0.5	nc	(nc-nc)	Female	74	61.1	121.1	(95.1-152.1)
<u>Lung and Bronchus</u>									
Male	4	6.4	nc	(nc-nc)					
Female	12	8.6	139.8	(72.2-244.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	10.6	94.3	(45.1-173.4)
Female	0	0.1	nc	(nc-nc)	Female	3	7.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	1	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.6	nc	(nc-nc)	Male	5	5.3	95.1	(30.6-221.8)
Female	4	2.8	nc	(nc-nc)	Female	5	3.7	136.5	(44.0-318.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.7	127.2	(46.4-276.9)
Female	28	30.7	91.2	(60.6-131.8)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	3	9.0	nc	(nc-nc)	<u>Ovary</u>				
Female	4	8.4	nc	(nc-nc)	Female	5	2.6	190.1	(61.3-443.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	32	26.7	120.0	(82.1-169.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	5	4.6	108.1	(34.8-252.3)	Female	2	1.1	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.1	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	7	6.7	103.8	(41.6-213.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.9	nc	(nc-nc)	Male	93	108.2	86.0	(69.4-105.3)
Female	1	0.9	nc	(nc-nc)	Female	99	103.2	95.9	(78.0-116.8)
<u>Lung and Bronchus</u>									
Male	14	15.4	91.2	(49.8-153.0)					
Female	16	14.6	109.4	(62.5-177.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	7.2	194.5	(106.2-326.3)	Male	4	5.3	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	9	4.3	208.4	(95.1-395.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.8	167.3	(72.0-329.7)
Female	35	35.7	98.2	(68.4-136.5)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	4.7	107.4	(34.6-250.6)
<u>Colon / Rectum</u>					Female	4	1.7	nc	(nc-nc)
Male	14	8.9	158.0	(86.3-265.1)	<u>Ovary</u>				
Female	14	8.0	176.0	(96.1-295.3)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	2.3	353.8	(152.3-697.1)	Male	2	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	20	31.0	64.6	(39.4-99.8)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	7	5.3	133.0	(53.3-274.0)	Female	2	1.1	nc	(nc-nc)
Female	5	2.7	188.4	(60.7-439.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.4	121.7	(55.6-231.1)
Male	1	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.3	217.4	(70.1-507.4)	Female	2	8.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	127	112.3	113.1	(94.2-134.5)
Female	0	0.9	nc	(nc-nc)	Female	123	111.5	110.3	(91.6-131.6)
<u>Lung and Bronchus</u>									
Male	15	13.9	107.8	(60.3-177.8)					
Female	16	14.0	114.0	(65.1-185.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	16	13.2	121.5	(69.4-197.2)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.7	nc	(nc-nc)
Male	5	3.6	140.8	(45.4-328.6)	<u>Ovary</u>				
Female	4	3.1	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	12.3	65.0	(28.0-128.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.3	nc	(nc-nc)	Male	39	45.4	85.8	(61.0-117.4)
Female	0	0.4	nc	(nc-nc)	Female	48	42.4	113.1	(83.4-150.0)
<u>Lung and Bronchus</u>									
Male	4	6.5	nc	(nc-nc)					
Female	3	6.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.8	61.1	(22.3-133.1)	Male	4	7.2	nc	(nc-nc)
Female	6	3.6	169.0	(61.7-367.8)	Female	6	5.8	104.2	(38.0-226.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.5	nc	(nc-nc)
Female	42	46.9	89.5	(64.5-121.0)	Female	2	5.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	10	12.3	81.5	(39.0-149.8)	<u>Ovary</u>				
Female	5	11.2	44.7	(14.4-104.2)	Female	3	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.9	171.9	(55.4-401.3)	Male	3	3.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	35	38.0	92.1	(64.2-128.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.6	nc	(nc-nc)
Male	7	6.8	102.5	(41.1-211.2)	Female	1	1.5	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.8	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.5	74.0	(29.7-152.5)
Male	6	4.4	136.8	(50.0-297.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.2	nc	(nc-nc)	Female	11	10.4	105.8	(52.8-189.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	127	147.1	86.3	(72.0-102.7)
Female	2	1.3	nc	(nc-nc)	Female	127	149.5	85.0	(70.8-101.1)
<u>Lung and Bronchus</u>									
Male	22	18.4	119.5	(74.9-181.0)					
Female	20	18.8	106.3	(64.9-164.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	12.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	7	11.4	61.4	(24.6-126.6)
<u>Lung and Bronchus</u>									
Male	1	1.8	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.1	127.1	(58.0-241.3)	Male	7	5.0	140.8	(56.4-290.2)
Female	1	2.4	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.4	112.6	(36.3-262.8)
Female	35	30.9	113.2	(78.8-157.4)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	6	8.4	71.8	(26.2-156.4)	<u>Ovary</u>				
Female	3	7.1	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	25	26.7	93.7	(60.6-138.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.0	99.3	(36.3-216.2)
Male	5	3.1	161.3	(52.0-376.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.0	nc	(nc-nc)	Female	12	6.8	175.5	(90.6-306.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	3.0	233.0	(93.4-480.1)	Male	96	102.4	93.8	(76.0-114.5)
Female	2	0.8	nc	(nc-nc)	Female	106	98.4	107.7	(88.2-130.3)
<u>Lung and Bronchus</u>									
Male	10	13.1	76.1	(36.5-140.0)					
Female	16	13.3	120.7	(68.9-196.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	11.1	135.5	(75.8-223.5)	Male	14	7.9	176.1	(96.2-295.5)
Female	2	4.9	nc	(nc-nc)	Female	5	7.1	70.0	(22.5-163.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	7.1	112.1	(48.3-220.9)
Female	61	60.0	101.6	(77.7-130.6)	Female	6	7.1	84.3	(30.8-183.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	11	6.5	168.7	(84.1-301.8)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	16	13.2	121.4	(69.4-197.2)	<u>Ovary</u>				
Female	13	14.8	87.6	(46.6-149.7)	Female	6	5.1	118.6	(43.3-258.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	52	41.6	125.1	(93.4-164.0)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.9	nc	(nc-nc)
Male	13	7.5	174.5	(92.8-298.4)	Female	0	2.0	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.1	90.2	(43.2-165.8)
Male	7	4.9	142.3	(57.0-293.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.1	122.1	(39.3-284.9)	Female	12	13.2	90.7	(46.8-158.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	105.7	(34.1-246.6)	Male	212	162.5	130.5	(113.5-149.3)
Female	2	1.7	nc	(nc-nc)	Female	178	194.7	91.4	(78.5-105.9)
<u>Lung and Bronchus</u>									
Male	30	20.8	144.2	(97.3-205.9)					
Female	25	26.5	94.3	(61.0-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	30.4	108.7	(74.8-152.6)	Male	22	19.5	113.1	(70.8-171.2)
Female	9	9.3	96.5	(44.0-183.2)	Female	22	13.9	158.7	(99.4-240.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.8	155.6	(71.0-295.3)	Male	3	6.3	nc	(nc-nc)
Female	7	4.4	159.7	(64.0-329.0)	Female	3	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	11	17.2	63.9	(31.8-114.3)
Female	128	111.9	114.4	(95.4-136.0)	Female	14	13.5	103.6	(56.6-173.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.9	nc	(nc-nc)	Male	13	14.2	91.6	(48.7-156.7)
<u>Colon / Rectum</u>					Female	6	5.8	103.3	(37.7-224.9)
Male	31	32.1	96.6	(65.6-137.1)	<u>Ovary</u>				
Female	27	27.9	96.7	(63.7-140.7)	Female	6	9.6	62.8	(22.9-136.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.8	89.5	(35.9-184.4)	Male	7	10.8	64.8	(26.0-133.5)
Female	0	1.9	nc	(nc-nc)	Female	11	9.6	115.1	(57.4-206.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	61	93.0	65.6	(50.2-84.3)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.3	68.2	(22.0-159.2)
Male	9	16.8	53.7	(24.5-101.9)	Female	2	3.8	nc	(nc-nc)
Female	12	8.6	138.9	(71.7-242.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	4.0	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	7.6	65.9	(21.2-153.8)
<u>Leukemia</u>					Female	23	21.5	107.1	(67.9-160.7)
Male	11	12.2	90.2	(45.0-161.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.8	76.6	(28.0-166.7)	Female	25	25.1	99.7	(64.5-147.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	10.6	56.8	(20.7-123.5)	Male	309	389.7	79.3	(70.7-88.6)
Female	3	3.2	nc	(nc-nc)	Female	398	367.0	108.5	(98.1-119.6)
<u>Lung and Bronchus</u>									
Male	42	55.0	76.3	(55.0-103.2)					
Female	61	49.3	123.7	(94.6-158.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.7	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	10	8.9	112.7	(54.0-207.4)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	7	2.1	325.9	(130.6-671.5)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	9.4	53.1	(17.1-123.8)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	6	2.1	279.3	(102.0-608.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.0	nc	(nc-nc)	Male	22	35.5	62.1	(38.9-94.0)
Female	1	0.3	nc	(nc-nc)	Female	33	28.8	114.7	(78.9-161.1)
<u>Lung and Bronchus</u>									
Male	4	4.9	nc	(nc-nc)					
Female	3	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;